“Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s66. doi:10.25251/skin.6.supp.66.